Cover Image
Market Research Report

Transthyretin Amyloidosis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Published by Coherent Market Insights Product code 769553
Published Content info 221 Pages
Delivery time: 2-3 business days
Price
Back to Top
Transthyretin Amyloidosis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
Published: December 31, 2018 Content info: 221 Pages
Description

Transthyretin amyloidosis is a rare inherited and slowly progressive disease characterized by abnormal buildup of deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Two main type of transthyretin amyloidosis includes hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. Hereditary transthyretin amyloidosis is further divided into polyneuropathy, cardiomyopathy, and mixed type.

Diagnosis of transthyretin amyloidosis includes approaches such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for diagnosis of the disease. Genetic testing for transthyretin gene mutations is performed in case of familial transthyretin amyloidosis diagnosis.

Market Dynamics

Approvals and launches of novel therapies for the treatment of transthyretin amyloidosis is expected to be a major factor driving the market growth over the forecast period. In October 2018, Eidos Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its drug candidate AG10, indicated for the treatment of ATTR.

In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)

Furthermore, increasing number under development drugs for the treatment of transthyretin amyloidosis are expected to gain approval in the near future. Therefore, presence of such robust pipeline is expected to boost the market growth. For instance, GlaxoSmithKline plc. a pharmaceutical company, is developing dezamizumab (2398852)† +2315698†, a combination of GSK2398852 (anti-SAP mAb) and GSK2315698 (CPHPC) for the treatment of amyloidosis. Currently, the product is under phase 2 clinical trial.

Key features of the study:

  • This report provides in-depth analysis of the global transthyretin amyloidosis treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018-2026)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global transthyretin amyloidosis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global transthyretin amyloidosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global transthyretin amyloidosis treatment market

Detailed Segmentation:

  • Global Transthyretin Amyloidosis Treatment Market, by Drug Type:
    • Tafamidis (Vyndaqel)
    • Patisiran (ONPATTRO)
    • Inotersen (TEGSEDI)
    • Others
  • Global Transthyretin Amyloidosis Treatment Market, by Disease Type:
    • Hereditary Transthyretin Amyloidosis
      • Polyneuropathy
      • Cardiomyopathy
      • Mixed Type
    • Wild Type Amyloidosis
  • Global Transthyretin Amyloidosis Treatment Market, by Distribution Channel:
    • Hospital Pharmacies
    • Specialty Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Transthyretin Amyloidosis Treatment Market, By Geography:
    • North America
      • By Drug Type:
      • Tafamidis (Vyndaqel)
      • Patisiran (ONPATTRO)
      • Inotersen (TEGSEDI)
      • Others
      • By Disease Type:
      • Hereditary Transthyretin Amyloidosis
      • Polyneuropathy
      • Cardiomyopathy
      • Mixed Type
      • Wild Type Amyloidosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Specialty Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Drug Type:
      • Tafamidis (Vyndaqel)
      • Patisiran (ONPATTRO)
      • Inotersen (TEGSEDI)
      • Others
      • By Disease Type:
      • Hereditary Transthyretin Amyloidosis
      • Polyneuropathy
      • Cardiomyopathy
      • Mixed Type
      • Wild Type Amyloidosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Specialty Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type:
      • Tafamidis (Vyndaqel)
      • Patisiran (ONPATTRO)
      • Inotersen (TEGSEDI)
      • Others
      • By Disease Type:
      • Hereditary Transthyretin Amyloidosis
      • Polyneuropathy
      • Cardiomyopathy
      • Mixed Type
      • Wild Type Amyloidosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Specialty Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • By Drug Type:
      • Tafamidis (Vyndaqel)
      • Patisiran (ONPATTRO)
      • Inotersen (TEGSEDI)
      • Others
      • By Disease Type:
      • Hereditary Transthyretin Amyloidosis
      • Wild Type Amyloidosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Specialty Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East
      • By Drug Type:
      • Tafamidis (Vyndaqel)
      • Patisiran (ONPATTRO)
      • Inotersen (TEGSEDI)
      • Others
      • By Disease Type:
      • Hereditary Transthyretin Amyloidosis
      • Polyneuropathy
      • Cardiomyopathy
      • Mixed Type
      • Wild Type Amyloidosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Specialty Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type:
      • Tafamidis (Vyndaqel)
      • Patisiran (ONPATTRO)
      • Inotersen (TEGSEDI)
      • Others
      • By Disease Type:
      • Hereditary Transthyretin Amyloidosis
      • Wild Type Amyloidosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Specialty Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Central Africa
      • South Africa
      • North Africa
    • North Africa
  • Company Profiles
    • Alnylam Pharmaceuticals, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Ionis Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Eidos Therapeutics, Inc.
    • Akcea Therapeutics, Inc.
    • Prothena Corporation Plc.
    • GlaxoSmithKline Plc.
    • SOM Innovation Biotech, S.L.
  • "*" marked represents similar segmentation in other categories in the respective section.
Table of Contents

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Disease Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Clinical Characteristics
  • Disease Diagnosis
  • Treatment Overview
  • Mechanism Of Action
  • Pipeline Analysis
  • Product Approval/Launches
  • Partnership- Collaboration Scenario
  • Epidemiology
  • Pest Analysis
  • Porter's Five Forces Analysis
  • Drivers
  • Restraints
  • Market Opportunities

4. Global Transthyretin Amyloidosis Treatment Market, By Drug Type, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Tafamidis (Vyndaqel)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Patisiran (ONPATTRO)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Inotersen (TEGSEDI)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

5. Global Transthyretin Amyloidosis Treatment Market, By Disease Type, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Hereditary Transthyretin Amyloidosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
    • Polyneuropathy
    • Cardiomyopathy
    • Mixed Type
  • Wild Type Amyloidosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

6. Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Specialty Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

7. Global Transthyretin Amyloidosis Treatment Market, By Geography, 2016 - 2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Geography, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Geography, 2017-2026
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Alnylam Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Ionis Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eidos Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Akcea Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Prothena Corporation Plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • SOM Innovation Biotech, S.L.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top